BACKGROUND: Retrospective evaluation of the effectiveness and adverse events (AEs) of a sequential chemotherapy regimen using @entity136 + @entity3003 (GCarbo) followed by GCarbo + @entity1205 (GCarboD) for advanced upper-tract @entity189 (UTUC). METHODS: We treated 56 @entity1 with advanced UTUC. Mean @entity1 age was 68.9 years, @entity1011 clearance was 51.2 mL/min, and the observation period was 20 months. @entity1 received two courses of GCarbo comprising 800 mg/m(2) @entity136 on days 1, 8, and 15, and @entity3003 at an area under the curve of four on day 2. If this regimen was effective, we administered two more courses of GCarbo; if the regimen was ineffective, we switched to two courses of GCarboD (70 mg/m(2)). RESULTS: Complete (n = 3) and partial response (PR; n = 25) were achieved after GCarbo. Mean response duration was 9.7 months. Two of 17 cases achieved PR after GCarboD treatment (mean duration, 31.5 months). Median survival was 14.0 months with the GCarbo/GCarboD regimen. Responders to GCarbo therapy survived significantly longer. AEs with the GCarbo regimen included 31 instances of G3/4 blood @entity137 and 8 instances of G3/4 @entity110 ; however, there were only 6 instances of G3/4 @entity344 . AEs with the GCarboD regimen included 16 @entity1503 and 8 instances of @entity344 . Neither regimen resulted in G3/4 @entity8 . CONCLUSIONS: GCarbo and GCarboD chemotherapy may be administered safely to @entity1 with advanced UTUC, with or without @entity8 . Response to GCarbo was high (50.0 %) whereas GCarboD was of limited effectiveness for non-responders to GCarbo.

Sequential chemotherapy using @entity136 + XXXX followed by @entity136 + @entity3003 + @entity1205 for advanced upper-tract urothelial cancer.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal toxicity', 'renal dysfunction'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal complications'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['instances of blood toxicity'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity110 :: ('MESH:D014581', 'Disease') :: ['urticaria']
@entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']
